NCT02386800 2026-03-16CINC424A2X01B Rollover ProtocolNovartisPhase 4 Active not recruiting279 enrolled
NCT04795427 2025-04-18Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsNovartisPhase 2 Completed84 enrolled
NCT06462365 2025-04-15Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)Tr1X, Inc.Phase 1 Recruiting36 enrolled
NCT02743351 2023-02-08Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic MalignanciesFate TherapeuticsPhase 1/2 Completed96 enrolled 13 charts
NCT02228382 2021-12-30Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase InhibitorsPfizerPhase 4 Terminated163 enrolled 27 charts
NCT01663766 2021-08-19Phase I Study of Milatuzumab for Graft Versus Host DiseaseGilead SciencesPhase 1 Terminated12 enrolled
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT02085798 2020-01-27Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)CelgeneCompleted503 enrolled
NCT00349518 2016-02-17Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLBristol-Myers SquibbPhase 2/3 Withdrawn